Overview Press Releases Events and Presentations Financials and Filings Stock Information Corporate Governance FAQs Email Alerts Madrigal press releases are available below. Search them by keyword or browse by date. Year None20232022202120202019201820172016 June 1, 2023 Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences May 11, 2023 Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference May 9, 2023 Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results April 18, 2023 Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial February 23, 2023 Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results February 8, 2023 Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences January 6, 2023 Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis Pagination Previous page Page 1 Current page 2
Madrigal press releases are available below. Search them by keyword or browse by date. Year None20232022202120202019201820172016 June 1, 2023 Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences May 11, 2023 Madrigal Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference May 9, 2023 Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results April 18, 2023 Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial February 23, 2023 Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results February 8, 2023 Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences January 6, 2023 Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis Pagination Previous page Page 1 Current page 2
May 9, 2023 Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results
April 18, 2023 Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial
February 23, 2023 Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results
February 8, 2023 Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
January 6, 2023 Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
